A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial

被引:5
|
作者
den Dekker, Bianca M. [1 ]
Christenhusz, Anke [2 ]
van Dalen, Thijs [3 ]
Jongen, Lisa M. [4 ]
van der Schaaf, Margreet C. [5 ]
Dassen, Anneriet E. [2 ]
Pijnappel, Ruud M. [1 ,6 ]
机构
[1] Univ Utrecht, Univ Med Ctr Utrecht, Dept Radiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Twente, Dept Surg, Med Spectrum Twente Enschede, Enschede, Netherlands
[3] Diakonessenhuis Utrecht, Dept Surg, Utrecht, Netherlands
[4] Diakonessenhuis Utrecht, Dept Radiol, Utrecht, Netherlands
[5] Med Spectrum Twente Enschede, Dept Radiol, Enschede, Netherlands
[6] Dutch Expert Ctr Screening, Nijmegen, Netherlands
关键词
Breast cancer; Localization; Breast conserving surgery; Radiofrequency identification; RFID; WIRE LOCALIZATION; EXPERIENCE; SURGERY;
D O I
10.1186/s12885-022-09394-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Breast cancer screening and improving imaging techniques have led to an increase in the detection rate of early, nonpalpable breast cancers. For early breast cancer, breast conserving surgery is an effective and safe treatment. Accurate intraoperative lesion localization during breast conserving surgery is essential for adequate surgical margins while sparing surrounding healthy tissue to achieve optimal cosmesis. Preoperative wire localization and radioactive seed localization are accepted standard methods to guide surgical excision of nonpalpable breast lesions. However, these techniques present significant limitations. Radiofrequency identification (RFID) technology offers a new, nonradioactive method for localizing nonpalpable breast lesions in patients undergoing breast conserving surgery. This study aims to evaluate the feasibility of RFID surgical guidance for nonpalpable breast lesions. Methods: This multicenter prospective cohort study was approved by the Institutional Review Board of the University Medical Center Utrecht. Written informed consent is obtained from all participants. Women with nonpalpable, histologically proven in situ or invasive breast cancer, who can undergo breast conserving surgery with RFID localization are considered eligible for participation. An RFID tag is placed under ultrasound guidance, up to 30 days preoperatively. The surgeon localizes the RFID tag with a radiofrequency reader that provides audible and visual real-time surgical guidance. The primary study outcome is the percentage of irradical excisions and reexcision rate, which will be compared to standards of the National Breast Cancer Organisation Netherlands (NABON)(<= 15% irradical excisions of invasive carcinomas). Secondary outcomes include user acceptability/experiences, learning curve, duration and ease of the placement- and surgical procedure and adverse events. Discussion: This study evaluates the feasibility of RFID surgical guidance for nonpalpable breast lesions. Results may have implications for the future localization techniques in women with nonpalpable breast cancer undergoing breast conserving surgery.
引用
收藏
页数:7
相关论文
共 4 条
  • [1] A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial
    Bianca M. den Dekker
    Anke Christenhusz
    Thijs van Dalen
    Lisa M. Jongen
    Margreet C. van der Schaaf
    Anneriet E. Dassen
    Ruud M. Pijnappel
    [J]. BMC Cancer, 22
  • [2] Nonradioactive surgical guidance with radiofrequency identification technology for locating nonpalpable breast lesions; Initial experiences of the RFID Localizer I Trial
    Christenhusz, A.
    Den Dekker, B.
    Van Dalen, T.
    Jongen, L.
    Van der Schaaf, M.
    Ten Haken, B.
    Pijnappel, R.
    Dassen, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S117 - S117
  • [3] First Reported Use of the Faxitron LOCalizer™ Radiofrequency Identification (RFID) System in Europe - Feasibility Trial, Surgical Guide and Review for Non-palpable Breast Lesions
    Malter, Wolfram
    Holtschmidt, Johannes
    Thangarajah, Fabinshy
    Mallmann, Peter
    Krug, Barbara
    Warm, Mathias
    Eichler, Christian
    [J]. IN VIVO, 2019, 33 (05): : 1559 - 1564
  • [4] The AXSANA trial (AXillary Surgery After NeoAdjuvant treatment): An international prospective multicenter cohort study of the EUBREAST study group to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)
    Banys-Paluchowski, Maggie
    Stickeler, Elmar
    de Boniface, Jana
    Gentilini, Oreste
    Thill, Marc
    Hartmann, Steffi
    Mangold, Marina
    Solbach, Christine
    Blohmer, Jens-Uwe
    Untch, Michael
    Appelgren, Matilda
    Kolberg, Hans-Christian
    Kuhn, Thorsten
    [J]. CANCER RESEARCH, 2021, 81 (04)